Stay updated on LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial

Sign up to get notified when there's something new on the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the treatment outcomes for people with pleural or peritoneal mesothelioma, focusing on the use of LMB-100 and pembrolizumab to potentially improve outcomes for individuals with these cancers.
    Difference
    0.1%
    Check dated 2024-06-06T14:36:38.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying that researchers look for individuals who meet certain health and treatment history requirements. Previously, this section indicated that no information was provided.
    Difference
    49%
    Check dated 2024-05-22T21:18:34.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:43:49.000Z thumbnail image

Stay in the know with updates to LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page.